Indications for CORLOPAM:
Adults: for the in-hospital, short-term (up to 48hrs) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. Children: for the in-hospital, short-term (up to 4hrs) reduction in blood pressure.
Give by continuous IV infusion. Doses from 0.01–1.6mcg/kg/min have been studied. Initial dose should be titrated upward or downward, no more frequently than every 15mins (and less frequently as goal pressure is approached) to achieve desired therapeutic effect. The recommended increments for titration are 0.05–0.1mcg/kg/min.
Give by continuous infusion pump appropriate for delivery of low infusion rates. Usual starting dose: 0.2mcg/kg/min; increased dosages of up to 0.3–0.5mcg/kg/min every 20–30mins were generally well tolerated.
Sulfite sensitivity. Glaucoma. Intraocular hypertension. Increased intracranial pressure. Acute cerebral infarction. Hemorrhage. Monitor BP, electrolytes. Pregnancy. Nursing mothers: not recommended.
Dopamine D1-like receptor agonist.
Avoid concomitant β-blockers.
Headache, flushing, nausea, hypotension, tachycardia, hypokalemia.
Generic Drug Availability:
Single-dose vial (1mL, 2mL)—1